Biocon is driven by its commitment to deliver affordable innovation for patients around the world. Its key innovations include world's first Pichia based recombinant human Insulin provided for patients in over 50 countries, marketed in India as INSUGEN®, insulin analogue Glargine, as BASALOG®. INSUPen® is the next generation German technology based affordable insulin delivery device introduced in India to ensure better compliance and management of diabetes.
Biocon is credited with introducing India's first indigenously developed monoclonal antibody BioMAb-EGFR®, for head & neck cancer in 2006 and has successfully developed and launched in India another Novel biologic Itolizumab, ALZUMAb™ for Psoriasis- a ‘first- in- class’ anti CD6 monoclonal antibody with a potential to address many autoimmune diseases.